Analytics

Equity Analytics

Equity Analytics/UCB.BR

UCB.BR

UCB SA

Healthcare - BE

UCB SA is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines and solutions for people living with severe neurological and immunology diseases. The company operates through…

HQ: Brussels, BU, Belgiumwww.ucb.com

EUR296.50+0.44%vs prev. close

Performance

+1.93%

+46.78%

+39.66%

+33.08%

YTD

+24.27%

Valuation

P/E

26.2

EPS TTM

11.32

Dividend yield

0.49%

Size and risk

Market cap

$62.5B

Beta

0.11

Next earnings

Report date

EPS estimate

Revenue estimate

Peer comparison

UCB
UCB.BR
Biotechnology
Mkt cap (USD bn)
62.5
P/E
26.2
Div yld
0.49%
1W
+1.9%
1M
+46.8%
3M
+39.7%
6M
+25.1%
1Y
+33.1%
YTD
+24.3%

Company	Ticker	Industry	Mkt cap (USD bn)	P/E	Div yld	1W	1M	3M	6M	1Y	YTD
UCB	UCB.BR	Biotechnology	62.5	26.2	0.49%	+1.9%	+46.8%	+39.7%	+25.1%	+33.1%	+24.3%

Subscribe to Equity Analytics to compare UCB.BR with its closest peers

Sector-matched peer set with side-by-side valuation, dividend and performance over every window.

View plans

Ask Ashenden

Ask, then keep asking: it follows the conversation for 30 minutes, grounded in Ashenden research.

Built on Ashenden research and our own data. Answers are AI-generated: they can be wrong or incomplete — check anything you would act on.

Equity Analytics

UCB.BR

Price history

Next earnings

Peer comparison

Equity Analytics

UCB.BR

Price history

Next earnings

Peer comparison